Taconic Biosciences News

Taconic Biosciences News is your source for current and relevant news on how animal models are being used to drive drug discovery. Use the links below to explore exciting announcements from Taconic via Press Releases, Taconic’s press activity in Media Coverage, and Taconic's commitment to being Models For Life™.

Special Report on Neuroscience: On good behavior

Special Report on Neuroscience: On good behavior

In a recent article published in Drug Discovery News, Taconic's Dr. Terina Martinez explains how behavior is influenced by multiple molecular pathways. She goes on to note that studies that aim to explore behavioral observations must be carefully designed and researchers should be very thoughtful in the interpretation of results. As a first step towards advancing neuroscience studies in humans, researchers should first conduct their studies in...  Read More

Special Report on Liver Disease: The phantom menace

Special Report on Liver Disease: The phantom menace

Non-alcoholic fatty liver disease (NAFLD) is a growing concern for clinicians and researchers, alike. One key problem with understanding how widespread this disease is, as it usually develops slowly and without symptoms. In a recent article for Drug Discovery News (DDN), Taconic's Field Applications Scientist Dr. Janell Richardson described how mouse models are helping advance research in this field. While no one model is perfect for modeling...  Read More

Minding the Microbiome of Your Mice

Minding the Microbiome of Your Mice

The microbiome is increasingly cited as a key regulator of health and disease. This article published in Lab Animal highlights the role of differing microbiomes from different animal model vendors, as well as the importance of maintaining a consistent microbiome to increase reproducibility. As mentioned, Taconic's TruBIOME solution enables researchers to develop a specific microbiota and maintain it for multiple generations of breeding. Read more here......  Read More

Taconic Candy Sale

Taconic Candy Sale

The Taconic Candy Sale originally started around 1999 as a fund raiser for the American Cancer Society's Relay For Life®. The Sale was so successful that what started as a single idea has evolved into a tradition still going strong after more than twenty years. Over that time Taconic has been able to donate money to various charities, while also providing a fun snack option for staff...  Read More

Taconic Biosciences to Distribute Critical COVID-19 Mouse Model

Taconic Biosciences to Distribute Critical COVID-19 Mouse Model

Signs Exclusive Agreement with University of Texas Medical Branch at Galveston to Access Humanized ACE2 Mouse Model Rensselaer, NY — June 22, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces an exclusive agreement with the University of Texas Medical Branch at Galveston (UTMB) to distribute humanized ACE2 mice for coronavirus research. The SARS-CoV-2 virus, which causes COVID-19, uses the ACE2...  Read More

Taconic Biosciences Expands Production of Critical Immunodeficient Model

Taconic Biosciences Expands Production of Critical Immunodeficient Model

Local Production of the CIEA NOG mouse® Model Now Available on the West Coast Rensselaer, NY, — June 10, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces local West Coast United States production of the immunodeficient CIEA NOG mouse® model. Immunodeficient animal models are critical to the drug discovery ecosystem. One of the most common contributors to the high product...  Read More

Taconic Biosciences Launches Rapid Restart™ Program

Taconic Biosciences Launches Rapid Restart™ Program

First Animal Model Provider to Create Program Aiding Researchers Planning for Return Rensselaer, NY, — May 18, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the successful implementation of its Rapid Restart™ program. Launched over a month ago, Taconic was the first animal model provider in the industry to provide researchers with a program specifically designed to aid laboratories transitioning...  Read More

Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

The 23rd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) will be taking place virtually from May 12-15, 2020. Intellia Therapeutics Inc., a company specializing in genome editing using CRISPR/Cas9, announced that five poster abstracts have been accepted for presentation at this meeting. One specific poster, titled "In Vivo Model Development for Genome-Edited T Cell Therapeutics", demonstrates the use of improved murine models...  Read More

Betting on the Bug: The Microbiome's Impact on Drug Efficacy

Betting on the Bug: The Microbiome's Impact on Drug Efficacy

Taconic's Dr. Alexander Maue recently authored a follow-up article for International Biopharmaceutical Industry (IBI) to his original comment on how the microbiome can improve reproducibility and translatability of animal models. In part two, he elaborates on how the microbiome can impact drug efficacy and what types of mouse models are being developed to further immuno-oncology research. Read the complete article at: biopharmaceuticalmedia.com...  Read More

Bitten By the Bug - A Flurry of Investments Fuel Microbiome Drug Discovery

Bitten By the Bug - A Flurry of Investments Fuel Microbiome Drug Discovery

Recent research into the microbiome demonstrates that the composition of gut microbiota influences the development and progression of disease. However, more research is needed to fully strengthen this connection. Taconic's Dr. Alexander Maue recently authored an article for Drug Discovery World depicting the investment landscape of biotech and pharmaceutical companies in the microbiome field. Dr. Maue describes how the number of IPOs, mergers & acquisitions, collaborations, and...  Read More